GTC
SNDX icon

Ghost Tree Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Ghost Tree Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300,000
Closed -$4.36M – 72
2023
Q3 		$4.36M Buy
+300,000
New +$5.67M 1.43% 22

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghost Tree Capital's SNDX Position: Q3 2024 in Review

Ghost Tree Capital increased its Syndax Pharmaceuticals (SNDX) stake by 29% in Q3 2024, buying an estimated $2.07M and bringing the position to 450,000 shares worth $8.66M. The position accounts for 2.62% of the portfolio, ranked #13.

Ghost Tree Capital first reported a position in SNDX in Q2 2017 and has held it in 19 quarters since. The position peaked at $30M in Q4 2020. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • Ghost Tree Capital held 450,000 shares of Syndax Pharmaceuticals worth $8.66M as of Q3 2024.
  • Ghost Tree Capital bought 100,000 Syndax Pharmaceuticals shares in Q3 2024, an estimated $2.07M.
  • Syndax Pharmaceuticals made up 2.62% of Ghost Tree Capital's portfolio in Q3 2024, its #13 holding.
  • Ghost Tree Capital first reported a position in Syndax Pharmaceuticals in Q2 2017 and has held it in 19 quarters since.
  • Ghost Tree Capital's Syndax Pharmaceuticals position peaked at $30M in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.